José Rioja

José Rioja

Auto-generated profile, based on publicly available information

José Rioja

Lipid and Atherosclerosis Laboratory (CIMES), Department of Medicine and Dermatology University of Málaga Málaga Spain

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 February 2008 in Endocrinology
Verified
Journal Article
Open access
JPJuan E. Puche
Juan E. Puche
Maria Garcia-FernandezMaria Garcia-Fernandez
Maria Garcia-Fernandez
JMJordi Muntané
Jordi Muntané
JRJosé Rioja
José Rioja
SGSalvador GonzálEz-Barón
Salvador GonzálEz-Barón
ICInma Castilla-Cortázar
Inma Castilla-Cortázar
Serum IGF-I levels decline with age. We have recently reported that in aging rats the exogenous administration of IGF-I restores IGF-I circulating levels and age related-changes, improving glucose and lipid metabolisms, increasing testosterone levels and serum total antioxidant capability, and reducing oxidative damage in the brain and liver associated with a normalization of antioxidant enzyme activities. Understanding that mitochondria are one of the most important cellular targets of IGF-I, the aims of this study were to characterize mitochondrial dysfunction and study the effect of IGF-I therapy on mitochondria, leading to cellular protection in the following experimental groups: young controls, untreated old rats, and aging rats treated with IGF-I. Compared with young controls, untreated aging rats showed an increase of oxidative damage in isolated mitochondria with a mitochondrial dysfunction characterized by: depletion of membrane potential with increased proton leak rates and intramitochondrial free radical production, and a significant reduction of ATPase and complex IV activities. In addition, mitochondrial respiration from untreated aging rats was atractyloside insensitive, suggesting that the adenine nucleotide translocator was uncoupled. The adenine nucleotide translocator has been shown to be one of the most sensitive locations for pore opening. Accordingly, untreated aging rats showed a significant overexpression of the active fragment of caspases 3 and 9. IGF-I therapy corrected these parameters of mitochondrial dysfunction and reduced caspase activation. In conclusion, these results show that the cytoprotective effect of IGF-I is closely related to a mitochondrial protection, leading to reduce free radical production, oxidative damage, and apoptosis, and to increased ATP production.

10 October 2014 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
NGNatalia García-Casares
Natalia García-Casares
RJRicardo E. Jorge
Ricardo E. Jorge
JGJuan A. García-Arnés
Juan A. García-Arnés
LALaura Acion
Laura Acion
MBMarcelo L. Berthier
Marcelo L. Berthier
PGPedro González-Santos
Pedro González-Santos
Background/Objective: The aim was to assess the neuropsychological performance of a group of middle-aged patients with well-controlled type 2 diabetes mellitus (T2DM) and to examine whether the neuropsychological deficits correlate with structural and functional brain alterations. Methods: We compared 25 subjects with T2DM aged 45–65 years with 25 control participants matched for age, gender, and educational level. The neuropsychological battery was designed to examine executive functions, attention, information processing speed, and verbal memory. Severity of depression was assessed using the Hamilton Depression Rating Scale and cardiovascular risk factors were assessed using the Framingham Cardiovascular Risk Profile Score. The presence of at least one APOEε4 allele was determined. Reduced gray matter density was analyzed using voxel-based morphometry and brain glucose metabolic changes were assessed by 18 FDG-PET. Results: T2DM subjects had significantly lower scores than subjects without T2DM in the Trail-making Test B (p < 0.004), Color-Word Stroop test (p < 0.005), Semantic Fluency (p < 0.006), Digit-Symbol modalities test (p < 0.02), Text Recall from the Wechsler Memory Scale (p < 0.0001), Rey-Osterrieth Complex Figure-copy (p < 0.004), and delayed reproduction (p < 0.03). Worse executive functions and memory functioning correlated predominantly with less gray matter density and reduced glucose metabolism in the orbital and prefrontal cortex, temporal (middle gyrus, parahippocampus and uncus), and cerebellum regions (p < 0.001). Conclusions: T2DM subjects presented cognitive dysfunctions compared with controls. Clinical-neuroimaging correlations corresponded to brain changes (reduced gray matter density and glucose metabolism) mainly in fronto-temporal areas.

31 March 2014 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
PDF file
GCGARCIA CASARES
GARCIA CASARES
MBMarcelo L. Berthier
Marcelo L. Berthier
RJRicardo E. Jorge
Ricardo E. Jorge
PGPedro Gonzalez-Alegre
Pedro Gonzalez-Alegre
ACAntonio Gutierrez Cardo
Antonio Gutierrez Cardo
PGPedro González-Santos
Pedro González-Santos
Background: Type 2 diabetes mellitus (T2DM) is an emerging risk factor for cognitive impairment. Whether this impairment is a direct effect of this metabolic disorder on brain function, a consequence of vascular disease, or both, remains unknown. Str

1 January 2009 in Cardiovascular Diabetology
Verified
Journal Article
Open access
PDF file
PVPedro Valdivielso
Pedro Valdivielso
JRJosé Rioja
José Rioja
CGCarlota García-Arias
Carlota García-Arias
MSMiguel Sánchez-Chaparro
Miguel Sánchez-Chaparro
PGPedro González-Santos
Pedro González-Santos
Mixed hyperlipidemia is common in patients with diabetes. Statins, the choice drugs, are effective at reducing lipoproteins that contain apolipoprotein B100, but they fail to exert good control over intestinal lipoproteins, which have an atherogenic potential. We describe the effect of prescription omega 3 fatty acids on the intestinal lipoproteins in patients with type 2 diabetes who were already receiving fluvastatin 80 mg per day. Patients with type 2 diabetes and mixed hyperlipidemia were recruited. Fasting lipid profile was taken when patients were treated with diet, diet plus 80 mg of fluvastatin and diet plus fluvastatin 80 mg and 4 g of prescription omega 3 fatty acids. The intestinal lipoproteins were quantified by the fasting concentration of apolipoprotein B48 using a commercial ELISA. The addition of 4 g of prescription omega 3 was followed by significant reductions in the levels of triglycerides, VLDL triglycerides and the triglyceride/HDL cholesterol ratio, and an increase in HDL cholesterol (P < 0.05). Fluvastatin induced a reduction of 26% in B100 (P < 0.05) and 14% in B48 (NS). However, the addition of omega 3 fatty acids enhanced this reduction to 32% in B100 (NS) and up to 36% in B48 (P < 0.05). Our preliminary findings therefore suggest an additional benefit on postprandial atherogenic particles when omega 3 fatty acids are added to standard treatment with fluvastatin.

29 April 2010 in BMC Medical Genetics
Verified
Journal Article
Open access
PDF file
MAMaria J. Ariza
Maria J. Ariza
MSMiguel-Ángel Sánchez-Chaparro
Miguel-Ángel Sánchez-Chaparro
Francisco Javier Barón-LópezFrancisco Javier Barón-López
Francisco Javier Barón-López
AHAna-María Hornos
Ana-María Hornos
ECEva Calvo-Bonacho
Eva Calvo-Bonacho
PGPedro González-Santos
Pedro González-Santos
Hypertriglyceridemia (HTG) is a well-established independent risk factor for cardiovascular disease and the influence of several genetic variants in genes related with triglyceride (TG) metabolism has been described, including LPL, APOA5 and APOE. The combined analysis of these polymorphisms could produce clinically meaningful complementary information.

1 January 2016 in Journal of Clinical Lipidology
Verified
Journal Article
Closed access
MAMaria J. Ariza
Maria J. Ariza
PMPedro Luis Martínez-Hernández
Pedro Luis Martínez-Hernández
DIDaiana Ibarretxe
Daiana Ibarretxe
CRClaudio Rabacchi
Claudio Rabacchi
JRJosé Rioja
José Rioja
PVPedro Valdivielso
Pedro Valdivielso